

Supplementary Table legends

Supplementary Table 1. List of primer sequences for qRT-PCR.

Supplementary Figure legends

Supplementary Figure 1. Cytotoxicity of Levamisole measured in BHK-21, LF-BK, ZZ-R, Murine PECs and Porcine PBMCs *via* cell viability assay.

Cell viability of BHK-21 cells (A), LF-BK cells (B), ZZ-R cells (C), Murine PECs (D), and Porcine PBMCs (E)

The data represent the mean \pm SEM of triplicate measurements. Statistical analyses were performed using two-way ANOVA with Tukey test.

Supplementary Figure 2. Assessment of induction of host defense against FMDV infection 3 days and 7 days after inoculation with levamisole alone in mice

Levamisole alone was injected intramuscularly into C57BL/6 mice that were challenged with FMDV O (100 LD₅₀ O/VET/2013) or FMDV A (100 LD₅₀ A/Malay/97) 3 days post-inoculation (dpi) and 7 dpi by intraperitoneal injection. Survival rates and body weights were monitored for 7 days post-challenge (dpc) with the respective viruses. (A) Experimental workflow, survival rates post-challenge with (B) O/VET/2013 or (C) A/Malay/97, and changes in body weight post-challenge with (D) O/VET/2013 or (E) A/Malay/97 at 3 dpv; survival rates post-challenge with (F) O/VET/2013 or (G) A/Malay/97, and changes in body weight post-challenge with (H) O/VET/2013 or (I) A/Malay/97 at 7 dpi. Data are presented as mean \pm SEM of triplicate measurements ($n = 5$ /group).


Supplementary Table 1

Target	Primer name	Sequence (5'- 3')	Length (mer)
RIG-I	RIG-I F	GCACCTCATACTTACAGCCCA	21
	RIG-I R	CCACAACCAGTAGGAGCACAT	21
TLR9	TLR9 F	TCCTCTACGACTGCATCACCA	21
	TLR9 R	GTAATTGAAGGACAGGTTGAGCTT	24
Dectin-1	Dectin-1 F	ACAGCTCCAAAGAGCTGGAA	20
	Dectin-1 R	CCAGCTCTTTGGAGCTGTCTA	20
hDectin-2	hDectin-2 F	GCTGAGTCTCTGGGCAACAT	20
	hDectin-2 R	TGAGGTTGCTGCTCTTGCAT	20
SYK	SYK F	CCAACCACTTGCCCTTCTTC	20
	SYK R	ATGGTGTAGTGATGCGCCTT	20
CARD9	CARD9 F	CCGCAGCTCTACAAGAAGGT	20
	CARD9 R	TCTGCAGCTTCATCACCTCG	20
hCARD11	CARD11 F	TGAACGAGGTCATCAAGCTG	20
	CARD11 R	AGCGTCAGCTGCTTCTTCTC	20
NF- κ B	NF- κ B F	TCGCTGCCAAAGAAGGACAT	20
	NF- κ B R	AGCGTTCAGACCTTCACCGT	20
BCL10	BCL10 F	ATGGAGCCCGCCGCGCCGTC	20
	BCL10 R	GCTATGATTTTTTCACACAG	20
MALT1	MALT1 F	GTTGGAAGCCCCATTCCACA	20
	MALT1 R	ACTCCACTGCCTCATCTGTTC	21
STAT1	STAT1 F	TGCACGATGGTCTCAGCTTT	20
	STAT1 R	CAGCAGTGGGACCAAGAAGT	20
IFN α	IFN α F	CATCTGCTCTCTGGGCTGTG	20
	IFN α R	TGAGGGGATCCAAAGTCCCT	20
IFN β	IFN β F	TGCAACCACCACAATTCCAGA	21
	IFN β R	GGTTTCATTCCAGCCAGTGC	20
IFN γ	IFN γ F	GCCATTCAAAGGAGCATGGAT	21
	IFN γ R	CTGATGGCTTTGCGCTGGAT	20
IL-1 β	IL-1 β F	AGCCAGTCTTCATTGTTTCAGGT	22


	IL-1 β R	TCATCTCTTTGGGGCCATCAG	21
IL-6	IL-6 F	CTGCAGTCACAGAACGAGTG	20
	IL-6 R	CGGCATCAATCTCAGGTGCC	20
IL-12p40	IL-12p40 F	GGAGTATAAGAAGTACAGAGTGG	23
	IL-12p40 R	GATGTCCCTGATGAAGAAGC	20
IL-17A	IL-17A F	CTCGTGAAGGCGGGAATCAT	20
	IL-17A R	GGTGTGCTCCGGTTCAAGAT	20
IL-18	IL-18 F	AGCTGAAAACGATGAAGACCTG	22
	IL-18 R	AAACACGGCTTGATGTCCCT	20
IL-23p19	IL-23p19 F	CCATATCCAGTGCGGGGATG	20
	IL-23p19 R	AGGCCTTGGTGGATCCTTTG	20
CD80	CD80 F	TCAGACACCCAGGTACACCA	20
	CD80 R	GACACATGGCTTCTGCTTGA	20
CD86	CD86 F	TTTGGCAGGACCAGGATAAC	20
	CD86 R	GCCCTTGTCTTGATTTGAA	20
CD28	CD28 F	TCAAAGGAGTTCGGGCATC	20
	CD28 R	CTGAAGCAGGCGGGAGTAAT	20
CD19	CD19 F	GGACGACAGACTTCCTGAGC	20
	CD19 R	GTTCTGGCCCATCAGGATTA	20
CD21	CD21 F	TGCCATGCCTACAAAGCTGA	20
	CD21 R	GTAGTAACCAGGGCGGCATT	20
CD81	CD81 F	TCAACAAGGACCAGATCGCC	20
	CD81 R	GAGCGTCTCGTGGAAAGTCT	20
HPRT	HPRT F	CCCAGCGTCGTGATTAGTGA	20
	HPRT R	GCCGTTCAGTCCTGTCCATA	20

Supplementary Figure 1


(A)




(B)




(C)



(D)




(E)




Supplementary Figure 2


(A)




(B)




(C)




(D)




(E)




(F)



(G)



(H)



(I)

